$ADHD to Present at Upcoming Investment Conferences

0
621

Alcobra Ltd. to Present at Upcoming Investment Conferences

 Alcobra Ltd. (ADHD), an emerging pharmaceutical company focused on the development of new medications to help patients with cognitive disorders, including Attention Deficit Hyperactivity Disorder (ADHD) and Fragile X Syndrome, today announced corporate presentations at the upcoming 28th Annual ROTH Conference and the Barclays Global Healthcare Conference.

28th Annual ROTH Conference
Date: Monday, March 14
Time: 1:00pm Pacific Time
Location: Ritz Carlton, Laguna Niguel, California
Presenter: David Baker, Chief Commercial Officer
Barclays Global Healthcare Conference
Date: Thursday, March 17
Time: 10:45am Eastern Time
Location: Loews Miami Beach Hotel, Miami, Florida
Presenter: Dr. Yaron Daniely, President & Chief Executive Officer
Webcast: https://cc.talkpoint.com/barc002/031516a_ae/?entity=72_U2Q8T5Q

About Alcobra Ltd.
Alcobra Ltd. is an emerging pharmaceutical company primarily focused on the development and commercialization of a proprietary drug candidate, MDX, to treat cognitive disorders including ADHD and FXS. For more information please visit the Company’s website, www.alcobra-pharma.com, the content of which is not incorporated herein by reference.

Contact:
U.S. Investor Contacts
LifeSci Advisors, LLC
Michael Rice	
646-597-6979	
mrice@lifesciadvisors.com

Media Inquiries	
Sam Brown, Inc.		
Mike Beyer	
773-463-4211		
mikebeyer@sambrown.com

Israel Investor Contact:
Alcobra Investor Relations
Debbie Kaye
+972-72 2204661
debbie@alcobra-pharma.com

LEAVE A REPLY

Please enter your comment!
Please enter your name here